Evaluation of Immunological Efficiency Among Patients Vaccinated Against Tick-Borne Encephalitis by Leonova G.N.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
10 
Evaluation of Immunological Efficiency  
Among Patients Vaccinated Against  
Tick-Borne Encephalitis 
Leonova G.N. 
Institute of Epidemiology and Microbiology,  
Siberian Branch of the Russian Academy of Medical Sciences, Vladivostok,  
Russia 
1. Introduction 
Tick-borne encephalitis virus (TBEV) widespread in the Eurasian continent is a member of 
the genus Flavivirus, family Flaviviridae. Human TBE cases are registered in more than 30 
countries of the world [Charrel RN et al., 2004]. TBEV is subdivided into three main subtypes 
according to its genetic structure and antigen specificity: European, Siberian, and Far 
Eastern ones [Holzmann H, et al.1992; Ecker M. et al. 1999]. Differences in nucleotide 
sequences of TBEV genome of these subtypes may reach about 20% [Loktev VB et al. 2007]. 
Probably, a high TBEV genetic diversity provides its differences in human pathogenicity. 
Human pathogenicity of European subtype TBEV is less marked; however, towards the east, 
a severity of infection increases as well as lethality [Loktev VB et al. 2007; Pogodina VV et al. 
2007]. In the Russian Far East, the lethality caused by this infection remains at the highest 
levels [Pavlenko et al. 2010]; for the last 40 years it has reached, on average, 17,5% [Leonova et 
al., 2006; Leonova, 2009]. A vaccination is known to provide the most reliable and effective 
protection from many virus infections. Tick-borne encephalitis (TBE) as a very danger 
infection for humans is not the exception as well. Practical application of different vaccines 
against tick-borne diseases shows that vaccination of the population is a key link in terms of 
mass TBE prevention in highly endemic territories [Kunz C., 2003; Onishchenko G.G., et al. 
2007]. 
Tick-borne encephalitis is considered to be the international health issue, because the 
number of risk areas and reported cases across Europe, Russia, and parts of Asia is 
increasing. The incidence of TBE has fluctuated considerably from year to year in many 
countries, but in the past decade the number of TBE cases has significantly increased in the 
Baltic states, the Czech Republic, and Germany, in addition to the countries previously 
considered to be free from TBE, such as Denmark (specifically the main island of Zealand), 
France, and Italy. A number of factors have been suggested to explain the growth of 
incidence including climate changes, extended travelling, and outdoor pursuits increasingly 
placing people in contact with infected ticks [Eckhardt Petri et al., 2010].  
Development of vaccine against TBE has started since the discovery of causative agent in 
1937. A group of discoverers, headed by already well known virologist prof. L.A. Zilber, 
understood that only vaccine can become a reliable protection from this dangerous disease. 
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As early as in 1938 a group of young virologists headed by E.N. Levkovich started working 
on a vaccine against tick-borne disease; they obtained the first formalin-inactivated brain 
vaccine from the Far Eastern TBEV strain Sofjin [Vanda Pogodina. 2001].  
In 1939, the study aimed to investigate the vaccine effectiveness was conducted in Oborsk 
forestry (Khabarovsk Region). Lethality was not registered among the vaccinated patients. 
Despite the obvious epidemiological effectiveness of this vaccine, it caused serious side 
effects in vaccinated patients. In some years, number of postvaccinal encephalitis reached 
1:20000 of vaccinated patients. Reduction of concentration of brain tissue from white mice in 
the vaccine up to 2.5% did not make it better [3]. Thus, a search for safer approaches to the 
development of new vaccine was necessary. In 1960, development of the vaccine against 
TBE using chick-embryo cell culture for the virus reproduction was a significant step to 
improve quality of the vaccine preparation. TBE strain Sofjin was reproduced in a cell 
culture of chick fibroblasts, inactivated by formaldehyde in a concentration of 1:2000, and 
virus antigen was absorbed on aluminium hydroxide. However, vaccination of patients 
showed that not only reactogenicity, but also protective characteristics of this vaccine were 
lower in comparison with formolated brain vaccine [Vorobyova MS et al., 2007]. 
At the same time, at the Tomsk Scientific Research Institute of Vaccines and Sera, a cultural 
vaccine was developed using western TBEV subtype. It’s immunological activity and 
protective characteristics were also insufficient [Leonova GN, 1997; Vorobyova MS et al., 2007]. 
From 1964, this vaccine was introduced in the Far East. It’s immunologic effectiveness in 
hemagglutination-inhibition reaction (HAIR) was 70% with low immunity stress in HAIR 
(GTM 1:15). Soon, on the Primorye Territory, single TBE cases were reported among the 
patients vaccinated three times and revaccinated [Dorokhova V.S. & Tatarinova L.G, 1969]. In 
1967, rate of vaccinated persons didn’t exceed 1.8% of urban population and 13.2% of 
villagers. A cumbersome vaccination protocol and short-term humoral immunity in the 
patients vaccinated with a formalin-inactivated liquid tissue culture vaccine constantly 
initiated research work on production immunologically more active vaccines.  
In the middle of 1980s at the Institute of Poliomyelitis and Viral Encephalitides, Academy of 
Medical Sciences of the USSR, a group of scientists headed by L.B. Elbert developed a new 
preparation technique of concentrated vaccine based on the TBE strain Sofjin of Far Eastern 
subtype. A specific activity of the obtained vaccine considerably exceeded activity of non 
concentrated preparation [Vorobyova MS et al., 2007]. Nowadays, this vaccine is widely used 
on endemic territories of the Russian Federation as a dry concentrated vaccine produced by 
M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides (IPVE) of Russian 
Academy of Medical Sciences (RAMS). The TBE strain 205 isolated in 1973 from ticks 
I.persulcatus on Khabarovsk Territory [Vereta et al., 1990] is now used as a master seed virus 
for Tomsk vaccine. From 1984, liquid tissue culture vaccine against TBE has being 
manufactured by scientific production association (SPA) “Virion” (affiliated with Federal 
State Unitary Enterprise (FSUE) SPA “MicroGen”) on the base of this strain which is a 
typical representative of Far Eastern subtype of TBE. From 2003 it has being produced as 
liquid tissue culture inactivated, purified, concentrated, and absorbed vaccine “EnceVir”. 
Additionally, in 1970s, the development of live vaccine based on the attenuated strain ТР-21 
of the Langat virus and antigenically similar naturally attenuated Elantsev strain, isolated 
from human blood on the territory of Siberia, provoked a great response in scientific world 
[Smorodintsev A.A.& Doubov A.V , 1986]. Although these developments did not have any 
practical application, the authors outlined scientific approaches to creation of such vaccines. 
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According to these authors, the prime advantage of such vaccines consisted in absence of 
clinical and pathomorphological signs of central nervous system damage after intracerebral 
administration to monkeys.   
In 1971, the first foreign inactivated tissue culture vaccine against TBE was developed in 
Austria on the base of the Neudorfl strain (western subtype of TBE) isolated from ticks I. 
ricinus. In 1980s, a new technique was implemented; this enabled to obtain a preparation up 
to 99% free of heterologous protein and to concentrate TBEV antigen. The vaccine was called 
“FSME-Immun-Inject” [Kunz et al. 1980]. In 1993, this vaccine produced by “Baxter 
Vaccines” (Austria – USA) was registered in Russia for adults (0.5 mL), and in 2006-2007 – 
for children 1-16 years old at half the volume (0.25 mL) [Vorobyova MS et al., 2007]. 
In 1998, another TBE vaccine manufactured by the German company “Chiron Behring” 
(currently “Novartis Vaccines and Diagnostics GmbH & Co KG”) was registered in Russia. 
This vaccine was based on the strain K-23 (western subtype of TBE) isolated from ticks I. 
ricinus. In Russia, the vaccine is used in two variants: “Encepur® Adults” and “Encepur® 
Children”. This high-purity vaccine, free of homologous and heterologous proteins, is 
practically a non-reactogenic preparation which is very important for evaluation of its safety 
[Zent et al. 2003]. The vaccine variants for adults and children differ only by the 
concentration of the virus antigen (1.5 mg/0.5 mL and 0.75mg/0.25 mL, respectively). So 
far, there have not been registered any TBE cases both in European countries and the 
Russian Federation among those vaccinated with this vaccine, unlike the other ones 
described above. 
Availability of the above TBEV strains for vaccine preparations to protect from the current 
virus population including different subtypes of TBEV was reported in several papers 
[Holzmann H et al., 1992; Leonova GN, et al., 2006; Leonova GN et al., 2007]. On the other hand, 
new genetically different variants within the Far Eastern subtype of TBEV were found. They 
were Oshima, Senzhang, Glubinnoe/2004-like strains, and the strain of hemorrhagic form of 
TBE [Loktev VB et al. 2007; Leonova GN & Pavlenko EV, 2009]. Genetic diversity of TBEV was 
detected, when all three main TBEV genotypes could circulate simultaneously on the same 
territory [Pogodina VV. et al., 2007]. Thereupon, it is often a problem for public health in 
geographically different Eurasian regions to decide what vaccine among those consisting of 
different genovariant strains would be the most effective for protection of the population 
against TBE. 
2. Characterization of the immune response to Encepur® Adult vaccine 
Vaccine Encepur® Adult is produced using strain K23, which belongs to European subtype 
of TBEV (Bock HL, et al. 1990). Nucleotide sequences of Far Eastern and European TBEV 
subtypes have only 78–82% similarity. This naturally raises the question whether the vaccine 
based on the European subtype of TBEV is protective against the Far Eastern subtype of the 
virus. We sought to evaluate specific humoral immune response in volunteers immunized 
with vaccine Encepur® in relation to Far East strains TBEV. 
We characterized genetic and antigenic variation among TBEV strains P-73, P-202 and P-69, 
isolated in Far Eastern region of Russia. Locations, dates and sources of isolation Far Eastern 
strains used in this study are presented in Table 1. Genotyping of strains P-73, P-202, and P-
69 unambiguously demonstrated that they belong to Far Eastern subtype of TBEV (Leonova 
G. et al. 2007). 
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TBEV strain Year of 
isolation 
Source of 
isolation 
Place of isolation Reference 
Primorye-73 (P-73) 1973 Human brain 
(lethal case) 
Dal’nerechensk 
region, Primorsky 
krai 
Leonova GN et 
al. 2004 
Primorye-202 (P-
202) 
1997 Leukocytes of 
healthy human 
after tick bite 
Ussuriisk region, 
Primorsky krai 
Leonova GN et 
al. 2004 
Primorye-69 (P-69) 2000 Leukocytes of 
healthy human 
after tick bite 
Nadezhdinsk 
region, Primorsky 
krai 
Leonova GN et 
al. 2004 
Table 1. TBEV strains used in the study  
The strains P-73, P-202, and P-69 are highly virulent for suckling mice. The invasivity index 
for these strains (the difference between log10 LD50 for intracerebral and subcutaneous 
challenge) were found to be 2.0, 1.4, and 0.7, respectively. Strains P-73 and P-69 were 
replicating efficiently in PEK cells (7.5 and 6.0 log TCID50/0.1 ml, respectively). However, 
strain P-202 was not able to replicate effectively in PEK cells—the titer did not exceed 
4.75±0.25 log TCID50/0.1 ml. An attempt to adapt P-202 to cell culture by several passages 
in PEK cells was unsuccessful. 
We also measured humoral immune response against these strains after complete 
vaccination of volunteers with Encepur® Adult. We have shown significant differences in 
levels of antibodies and the number of NT-positive sera against strains P-73, P-202, and P-69 
1 year after the second immunization (Table 2). After the third immunization, key 
parameters of the immune response increased considerably and the number of sera positive 
in NT with strain P-202 reached 95.5±3.1 and 97.6±2.3% with strain P-73. The strain P-69 
behaved differently, as the number of sera positive in NT was only 63.9±7.2%, which is 
statistically different from the corresponding data for the other strains.  
 
No. of positive human 
sera (%) 
Maximal titer Average titera 
TBEV strain 
Before After Before After Before After 
P-73 (a) 56.8 95.5 80 640 19.7 128 
P-202 (b) 52.3 97.6 40 320 15 34 
P-69 (c) 27.3 63.9 20 80 11.3 28 
a Mean geometric titers of neutralizing antibodies. 
Table 2. Titers of neutralizing antibodies to TBEV strains P-73, P-202, and P-69 in volunteer’s 
sera before and after the third immunization with the vaccine Encepur® Adult (n = 44) 
Note: Reverse titer values are shown. Statistical significance: before immunization for (a–b) P 
< 0.05; for (a–c) and (b–c) P < 0.01, after immunization for (a–b) and (a–c) P < 0.001; for (b–c) 
P < 0.01. 
The most complete immune response to immunization with the German vaccine Encepur® 
Adult was achieved against highly virulent Far Eastern strain P-73. The volunteers were also 
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seemed to be protected against the two other TBEV strains. Induction of neutralizing 
antibodies at titers considerably exceeding the minimal protection level was demonstrated 
after both double and triple immunizations. 
3. Comparative evaluation of immunologic activity of vaccines against TBE 
used in the Russian Federation  
In Russia, the following vaccines are certified and widely used: “FSME-IMMUN-Inject” 
(Austria), “Encepur® Adults” (Germany), and two local vaccines – the TBE vaccine 
manufactured by M.P. Chumakov Institute of Poliomyelitis and Viral Encephalitides 
(Moscow, Russia) and “EnceVir” manufactured by SPA “MicroGen” (Tomsk, Russia) 
[Vorobyova MS, 2007].  
We have performed cohort and simultaneous study of immunologic effectiveness of the four 
vaccines against TBE in relation to several contemporary Far Eastern TBEV strains on 290 
volunteers [Leonova GN & Pavlenko EV, 2009]. We evaluated immunologic activity of the 
vaccines against TBE according to the intensity of antibody response one and two years later 
after full course of immunization with the vaccines. Postvaccinal antibody response was 
evaluated by a level of virus neutralizing antibodies, total antivirus antibodies, and their 
avidity regarding different TBEV strains.  
All volunteers were vaccinated three times during one year according to application 
instructions of the vaccines. The exception was made for a combined vaccination which 
consisted of alternate use of the Russian and foreign vaccines.  
The mean age of the vaccinated patients was almost the same, and in the first period of 
study it varied from 32.6 to 47.3 years, in the second one – from 34.7 to 47.4 years. Blood sera 
of the volunteers vaccinated against TBE were studied by enzyme-linked immunosorbent 
assay (ELISA) and neutralization test (NT) with the strain Рrimorye-73 (P-73) of Far Eastern 
TBE subtype.  
We have concluded that all studied vaccines are able to induce neutralizing antibodies 
against contemporary TBEV strains [Leonova GN & Pavlenko EV, 2009]. Levels of 
seroconversion for the vaccine “FSME-IMMUN-Inject” (Austria) were 88.2% in the year after 
full course of immunization and 78.1% of cases – two years later, “Encepur® Adults” 
(Germany) – 100% and 100%, the vaccine manufactured by IPVE RAMS (Moscow) – 100% 
and 94.1%, “EnceVir” (Tomsk) – 88.2% and 83.9%, and during the combined vaccination – 
100% and 92.7% of cases, respectively. Use of different types of vaccines during the 
combined vaccination of a patient provided a high and stable level of seroconversion 
according to NT, which is important for revaccination with different vaccines available in 
order not to interfere with the recommended vaccination protocols (Table 3).  
As a rule, antibodies with high affinity and avidity to surface proteins of TBEV virions are 
necessary for manifestation of neutralizing antibody activity. Only these antibodies do not 
allow the virus to interact with receptors and enter the cell. We have shown a variability of 
common and avid antibodies to different TBEV strains in vaccinated patients in the year of 
vaccination and two years later. Not all sera of those vaccinated with different vaccines had 
high-avid antibodies to the studied TBEV strains even in the year of vaccination.  
Moreover, not only the proportion of patients having antibodies and the general GMT of 
antibodies, but also GMT of avid antibodies to all TBE strains decreased at remote 
observation time (two years later after the vaccination course). It has been shown using 
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ELISA (Fig. 1) that in the year of vaccination, GTM of antibodies to TBEV reached 6.5 log2; 
two years later, GMT decreased up to 5.5 log2. 
 
Mean age 
Vaccine 
Observation 
time point 
Number of 
examined 
vaccinated 
persons years p 
ELISA 
(IgG %) 
NT 
(Ab %) 
After the 
primary 
vaccination 
course 
51 32.6 ± 2.3 86.3 88.2 
FSME-Immune 
Inject 
(«Baxter 
Vaccine», 
Austria) 
2 years after 
vaccination 
32 34.7 ± 3.3 
0.592 
75 78.1 
After the 
primary 
vaccination 
course 
6 36.8 ± 6.0 83.3 100 
Encepur® 
Adults 
(«Novartis 
Vaccines», 
Germany) 
2 years after 
vaccination 
11 46.4 ± 3.0 
0.128 
100 100 
After the 
primary 
vaccination 
course 
30 41.2 ± 3.3 90 100 
Vaccine by 
Chumakov 
Institute of 
Poliomyelitis 
(Moscow, 
Russia) 
2 years after 
vaccination 
17 47.4 ± 4.7 
0.274 
94.1 94.1 
After the 
primary 
vaccination 
course 
17 45.8 ± 4.5 76.5 88.2 EnceVir 
(«Microgen» 
Tomsk, Russia) 
2 years after 
vaccination 
56 45.6 ± 2.7 
0.971 
66.1 83.9 
After the 
primary 
vaccination 
course 
29 43.2 ± 3.9 100 100 
Combined 
vaccination* 
2 years after 
vaccination 
41 45.6 ± 2.6 
0.596 
92.7 92.7 
* The first two inoculations have been made by foreign vaccines consisting of the TBEV strains of 
European subtype, the subsequent booster vaccination − by the Russian vaccines consisting of the TBEV 
strains of Far Eastern subtype. 
Table 3. Comparative assessment of the immune response in patients vaccinated with 
different TBE vaccines after the primary vaccination course and the two years later after the 
primary vaccination course. 
Note: NT, neutralization test; Ab, the antibodies to TBEV strain p-73; p, significance at the 
confidence interval of 95% 
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Fig. 1. Distribution of IgG avidity index in the patients vaccinated against TBE after the 
primary vaccination course and two years later after vaccination: ♦, blood samples after the 
primary vaccination course; ○, blood samples two years later after vaccination; trend line 1, 
after the primary vaccination course; and trend line 2, two years later after vaccination 
Immune response of the patients vaccinated against TBE to different strains is known to 
vary [Holzmann al, 1992; Klockmann U. Et al,, 1999]. Figure 2 depicts comparative data on 
blood sera of the patients vaccinated against TBE in the first and second year after full 
course of vaccination studied by ELISA and indirect immunofluorescence assay (IFA). It is 
obvious that during both observation periods, antibodies of the vaccinated patients showed 
a closer immune relation to the strain P-73 in comparison with the other strains (P-202 and 
P-69) isolated from blood of the patients with inapparent TBE form. These data gave 
evidence that vaccinated patients had immunoprotection not only to pathogenic TBEV 
strain associated with focal form of infection with fatal outcome, but also to all other TBEV 
strains widely circulating on the territory of the Far Eastern region.  
Therefore, all four vaccines against TBE can be recommended for wide use in the Russian 
Far East (possibly in China and Japan as well), where the most pathogenic TBEV strains 
circulate. Virus-specific antibody avidity test have a special significance for more adequate 
evaluation of a stress of postvaccinal immune response. Avidity of specific IgG antibodies 
characterizes immune response of the vaccinated patients more precisely. It is also 
important to study functional antibody activity of the vaccinated patients for evaluation of 
their protection, when it is necessary to determine immunity stress of these patients 
regarding TBEV, for example, after tick bite. Indeed, such studies are necessary for 
determination of immunity duration in vaccinated patients and time of remote 
revaccinations. Use of different types of vaccines for immunity formation in a patient also 
provided a high and stable seroconversion according to NT. These data have a practical 
importance to determine time of remote revaccinations using another type of vaccine 
against TBE and consider interchangeability of all four types of vaccines without any 
interference with recommended vaccination protocol. Such approach can also provide 
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formation of a more diverse immunity against the strains of western and Far Eastern 
subtypes of TBEV. 
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Fig. 2. Rate of avid antibodies in patients vaccinated against tick-borne encephalitis after the 
primary vaccination course and two years later: IgG according to ELISA and the antibodies 
to P-73, P-202, and P-69 strains according to IFA;  A − percentage of avid antibodies after the 
primary vaccination course; B − percentage of avid antibodies two years later after 
vaccination 
4. Protective antibody titer and level of immunological memory in patients 
vaccinated against TBE  
The notion of protective antibody titer appeared during the studies on evaluation of 
vaccinal immunological activity. Preventive effectiveness of vaccines against some infections 
was considered to be evaluated by a protective level of immunological characteristics [Briko 
NI. 2004]. In 1980 Kunz et al. [1980] suggested that the protective titer of hemagglutinating 
antibodies for TBEV vaccine is above 1:10. At present time the most of diagnostic 
laboratories use ELISA as the main standard detection method of specific IgG antibodies.  
In the course of time, despite the decrease in characteristics of immune response, some 
vaccinated patients showed the ability to preserve antibodies for a long time [Kunz C. et al.. 
2003; Heinz FX, et al,. 2008]. To determine a revaccination time, we have obtained the 
experimental evidence of protective effect of different antibody titers in patients vaccinated 
against TBE. Immunological characteristics obtained during examination of the vaccinated 
patients, allowed us to indirectly judge a possible epidemiological effectiveness of vaccinal 
prevention. 
www.intechopen.com
Evaluation of Immunological Efficiency  
Among Patients Vaccinated Against Tick-Borne Encephalitis 
 
203 
4.1 Experimental studies (experiment №1) 
We performed the set of experiments using the specific anti-TBE immunoglobulin (titer 
from 1:6400 in ELISA, 1:160 – in IFA, and 1:320 – in NT).  To find an optimum alternative of 
experimentation, we ranged experimental components by IFA: different dilutions of 
immunoglobulin containing antibodies of IgG class, different TBEV doses and time 
parameters. Fig. 3 (А, В, С) shows influence of different TBEV doses (1, 2, 3 lg TCID) on the 
specific antibodies with titers ranging from 1:160 to 1:10 (via IFA) at 5, 15 and 30 min. In 
experimental samples, virus titers had from two- to four-fold decrease depending on virus 
dose employed in experiment. The most convincing data on the decrease of virus titer can be 
observed in Fig.3 C. With the virus dose 3 lg TCID50, the characteristics decreased 
significantly at all exposition times (5 – 30 min). 
Further studies were carried out with samples containing different dilutions of 
immunoglobulin and only a virus dose of 3 lg TCID50. Similar results were observed in 
ELISA and neutralization test (NT).  While observing the antibody contact at different 
dilutions (antibody titers from 1:6400 to 1:12.5) with TBEV (3 lg TCID50), we singled out the 
sample containing IgG with a titer of 1:400, in this sample the antibodies completely 
bounded to the virus antigen (Tabl. 4). 
Virus antigen in this sample decreased to minimal values (K = 0.4). During the experiment, 
K values of virus antigen were ambiguous: with high titre values (1:6400 and 1:1600) K 
antigen was positive (3.9 and 1.6, respectively), then K antigen decreased up to 0.4. 
However, the further decrease of IgG titers led to the increase of K antigen up to the positive 
value (1.0). RT-PCR data were positive in all samples. Occurrence of free infective virus of 
0.9 and 1.0 lg TCID50 was an evidence of unfavourable conditions for a specific protection in 
samples with IgG titer less than 1:100. Similar results were observed in neutralization test, 
when the minimal protective threshold having the starting titer was analysed with that of 
1:20. 
 
ELISA Neutralization test 
Initial 
IgG titer 
Residua
l IgG 
titer 
Initial IgG 
titer 
Residual 
IgG titer 
Antigen К 
via ELISA 
TBEV 
titration 
on PEK 
cells 
RT-PCR 
6400 1600 320 80 3,8 0 + 
3200 800 160 80 1,6 0 + 
1600 400 80 80 0,8 0 + 
800 200 40 40 0,5 0 + 
400 0 20 20 0,4 0 + 
200 0 10 0 1.0 0 + 
100 0 5 0 0,8 0 + 
50 0 2,5 0 0,7 0,9 + 
0 0 1,22 0 0,9 1,0 + 
Table 4. Experimental substantiation of protective IgG titer threshold under the influence of 
TBEV exposure (3 lg TCID50) based on ELISA, Nt, virus titration, RT-PCR, and antigen 
detection via ELISA 
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Fig. 3. Influence of different TBEV doses (А- 1 lg, В- 2 lg, С- 3 lg TCID50) on IgG titer in 30 
min (P1), 15 min (P2) and 5 min (P3), (P4 – control two-fold IgG dilutions 1:160-1:10) via IFA  
Х-axis – sample number; Y-axis (left) – IgG titer via IFA TBEV vaccine was above 1:10. At 
present, most of diagnostic laboratories use ELISA as the main standard method of specific 
IgG antibodies detection 
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Fig. 4 depicts two-fold decrease of specific IgG (2) titers under the TBEV influence at a dose 
of 3 lg TCID50. In addition, via IFA, it shows a gradual decrease in antigens (3) from the 
sample with IgG titer of 1:3200 to the one of 1:400 under the TBEV influence (3 lg TCID50). 
 
 
Fig. 4. Initial IgG titer (1), decrease of IgG titer (2), decrease of antigen titer (3), neutralization 
of TBEV  
3 lg TCID50 (4) in samples with serial two-fold IgG dilutions. 
Х-axis – sample number  
Y1-axis (left) – IgG titer via ELISA, Y2-axis (right) – antigen titre via ELISA  
There is also the virus neutralization from the sample with IgG titer of 1:3200 to the one of 
1:100. With the further antibody dilution (1:50 and 1:25) on the monolayer of the pig embryo 
kidney (PEK) cell culture, a cytopathic effect of non-neutralized virus with a titer of 0.9 and 
1.0 lg TCID50 was detected in the samples. 
4.2 Experimental studies (experiment №2) 
To confirm the obtained data, we performed the second set of experiments (in vivo and in 
vitro). TBEV doses from 1 to 8 TCID50 were compared via neutralization by immunoglobulin 
(titers 1:3200 and 1:400). Titration in PEK cells (Fig. 5 A) showed that IgG (titer 1:400) 
entirely neutralized 3 lg TCID50 of TBEV as in the first set of experiments, and IgG (titer 
1:3200) neutralized 4 lg TCID50. Moreover, after IgG treatment (titer 1:3200), initial virus titer 
(5-6 lg TCID50 or 7-8 lg TCID50) was reduced by 3-4 lg TCID50 or 1-2 lg TCID50, respectively. 
Titration on mice (Fig. 5 B) showed that IgG (1:400) entirely neutralized TBEV at 3 lg LD50 
and decreased TBEV titer by 3-4 lg LD50 in comparison with the initial 4, 5, 6 lg LD50, but 
was unable to neutralize 7 and 8 lg LD50. IgG with titer of 1:3200 entirely neutralized 5 lg 
LD50 and decreased TBEV titer of 6, 7 and 8 lg LD50 by 5.5 lg LD50, 3 lg LD50, and 2 lg LD50 of 
TBEV, respectively. 
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Fig. 5. IgG protective effect with titers of 1:400 (1) and 1:3200 (2) against TBEV (1-8 lg TCID50 
(A) & 1-8 lg LD50(B) 
A – PKE cells (in vitro); B – white mice (in vivo); 
Х-axis – sample number  
According to our data on neutralization of different IgG antibody titers with one dose of 
TBEV (3 lg TCID50), we considered a lower threshold of antibody protective level to be 1:400 
in ELISA and 1:20 in NT. The second set of experiments confirmed that in ELISA IgG titer of 
1:400 should be considered as the lower threshold of antibody protective level, and this 
threshold can be used for evaluation of immunological effectiveness of vaccines used for 
TBEV prevention.  
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Therefore, the set of experiments on neutralization of different antibody titers of IgG class 
with one TBEV dose (3 lg TCID50) allowed us to consider a minimal protective antibody 
threshold level to be at 1:400 via IFA and 1:20 via NT. Additional evidence was obtained 
during neutralization of TBEV with different titers using immunoglobulin having maximal 
(1:3200) and minimal (1:400) antibody titers. These experiments confirmed the suggestion 
that IgG titer of 1:400 for IFA should be considered the minimal protective antibody 
threshold level. It can be used for evaluation of immunologic effectiveness of vaccines used 
to prevent from TBE. Additionally, antibody titer of 1:100 can be considered as a lower 
threshold of immunological memory.  
Here we used TBEV at suboptimal doses of 1, 2, 3 lg TCID50 which are usual for tick bites on 
humans. As a rule, such doses occur in nature not only in ticks (Ixodidae), but also in 
Muridae rodents as their main hosts. The viremia in these rodents may overweight 
infectivity threshold (2.7 – 3.0 lg LD50 of TBEV) and, thus, ensure the virus transfer to ticks, 
as well as the stable virus circulation in environment [Chunikhin et al. 1985]. Nevertheless, 
cases of tick infection with TBEV over the mentioned threshold, if compare with theoretical 
possibility, are rather rare. It is, in turn, a protective factor which provides a relatively low 
number of TBE cases.  
Thus, at epidemiologically crucial virus dose of 3 lg TCID50, IgG protective effect was 
observed in experimental samples from the titer of 1:6400 to 1:100. Hence, we consider that 
the antibody titer of 1:100 not as a protective threshold level according to Sanitary and 
epidemiologic rules and regulations of the Russian Federation [Sanitary and epidemiologic 
rules and regulations SP 3.1.3.2352-07. 2008], but a lower threshold of immunological 
memory which allows a vaccination course to be continued. At the same time, patients 
vaccinated against TBE and having antibody titer of 1:100 in their blood can not to fall ill, 
provided that after a tick bite, the virus titer penetrated into blood was very low. However, 
a possibility of TBE disease still remains. Moreover, in the group of vaccinated patients, 
there are tick bite cases followed not only by febrile TBE form, but also sometimes by a 
clinical picture of brain damage. In addition, it has been shown that high IgG titers (1:3200) 
actively neutralized TBEV and, obviously, were able to provide a reliable protection from 
this disease. In the second set of comparative experiments on neutralization of different 
TBEV doses (from 1 to 8 lg) with immunoglobulin and antibody titers of 1:400 and 1:3200, 
we obtained additional evidence that the IgG titer of 1:400 is a minimal protective antibody 
threshold level. The obtained data can be used at any postvaccinal time for observation on 
immunological effectiveness of vaccinal prevention. Antibody titers of 1:400 and below 
indicate that revaccination is necessary.  
4.3 Evaluation of immunological effectiveness of vaccine Encepur® Adults 
In our earlier studies [Leonova et al. 2006; Leonova, 2009], we noticed that during the whole 
course of three-fold vaccination, antibodies of IgG class were observed in all blood samples, 
in 100% of cases, when the patients had specific antibodies (seropositive group) before 
undergoing full course of immunization. In seronegative group, antibodies of IgG class 
increased dynamically during the whole course of vaccination. However, characteristics of 
immune response stress according to NT data were of special interest. In seropositive group, 
titers of the virus neutralizing antibodies after the third vaccine were significantly behind 
the ones in seronegative group (GTM 1:208). Such lag was evidence that the patients of this 
group had got an excessive antigen stress on the immune system which resulted in a 
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considerable exhaustion and decrease in activity of immune response. This data should be 
taken into account when determining time of revaccinations.  
We evaluated immunological effectiveness of vaccine Encepur® Adults in remote periods 
after the primary course of vaccination. We analyzed blood sera of the patients (n=10) three 
and five years later after the vaccination. ELISA data (Fig. 6) showed that IgG titers in the 
patients were high three years later after full course of vaccination: 1:3200 – six cases, 1:1600 
– one case, 1:800 – one case and 1:400 – two cases. The avidity index of these antibodies was 
high or had a mean value. Five years later, characteristics of immune response decreased: 
IgG 1:3200 remained in three cases, 1:1600 – two cases, 1:800 – two cases, 1:400 – two cases, 
and 1:200 – one case. The avidity index also decreased: it had the mean value in five cases 
and was lower in another five cases. 
 
 
Fig. 6. The level of specific antibodies of patients immunized by Encepur® Adults 
1 – IgG level three years later after immunization; 
2 – IgG level five years later after immunization; 
3 – antibody avidity later three years after immunization; 
4 − antibody avidity five years after immunization 
Х-axis – sample number  
Y-1 axis (left) – IgG titer via ELISA, Y-2 axis (right) – IgG titer via NT 
Then, we continued studying immune response in this group of patients (n=15) in the last 
observation period, seven years later after full course of immunization, and one month later 
after the first revaccination (RV1). It was determined that before RV1, the percentage of 
patients with IgG antibodies according to IFA was 93.3% and GMT − 1:1120. Avid 
antibodies were found in 80% of the vaccinated patients, avidity index (AI) ranged from 45.2 
to 91.4%, and was 69.6±4.5% at the mean. After RV1, the values of immune response 
increased in these patients. We found specific antibodies in 100% of the patients. The stress 
of immune response was: IgG GMT – 1:3200 and AI – 83.6±4.8% (р=0,047).  
The results of this study gave us evidence on reasonability of a selection of TBEV antigen 
stress in the vaccine Encepur® Adults having not only high values of immune response, but 
www.intechopen.com
Evaluation of Immunological Efficiency  
Among Patients Vaccinated Against Tick-Borne Encephalitis 
 
209 
also a long-term protective effect [Zent et. al. 2003; 2005; 2005]. Additionally, using IFA, we 
performed the comparative analysis of immunogenic activity of the vaccine Encepur® 
Adults to the TBEV strains P-73 (Far Eastern subtype) and Kolarovo (Siberian subtype) 
isolated from the ticks I. pavlovskiy. Before revaccination, the percentage of patients with 
antibodies to these strains was 100% while GMT to the strain Р-73 was 1:91 and to the 
Kolarovo strain – 1:158. After revaccination, GMT to the strain Р-73 was 1:239 and to the 
Kolarovo strain − 1:447. These data are evidence of a higher level of antibodies to the 
Siberian TBEV subtype in the vaccinated patients in comparison with that of the strain Р-73 
of Far eastern TBE subtype, thus, making a good reason to recommend using this vaccine 
not only in European countries and Far East, but also on the whole focal territory of Siberia.  
For the first time, we obtained evidence for the lower threshold level of protective IgG titer 
in different experiments. Therefore, at the virus dose of 3 lg TCID50, protective effect of IgG 
was detected with titers ranging from 1:6400 to 1:100. Cytopathic effect was not registered in 
the PEK cell culture infected with these samples. We considered a lower threshold of 
protective IgG activity to be 1:400 according to ELISA data, and 1:20 according to NT. 
Although this sample was positive according to RT-PCR, we did not identify virus antigen 
in ELISA, and antibodies in the examined sample eliminated completely. With the further 
decrease of antibody titer, we observed an increase in characteristics of K values via antigen-
detection ELISA. Moreover, free infective virus up to 1lg TCD50 appeared in the samples 
with IgG titer lower than 1:100 (ELISA data). Due to this fact, we considered that antibody 
titer of 1:100 can not be called a threshold of protective level as it was reported by [Leonova 
G.N., 2009], but a lower threshold of immunological memory enabling further vaccination. 
Patients vaccinated against TBE with antibody titer of 1:100 in blood cannot fall ill after a 
tick bite, if they receive a relatively low virus dose. However, the possibility of TBE infection 
still remains. In addition to febrile forms of disease, there are also some cases of severe 
damage of nervous system occurring among immunized patients. Moreover, high IgG titers 
(1:3200) actively neutralized TBEV and were probably capable of ensuring a safeguard 
against this disease. The second set of comparative experiments on neutralization of 
different TBEV doses (from 1 to 8 lg) with IgG titer of 1:400 and initial antibody titer of 
1:3200 gave the additional evidence that IgG titer 1:400 is a minimal level of protective 
antibody activity. These data can be used at any time of observation after vaccination of the 
patients to evaluate the immunological effectiveness of vaccines used for TBEV prevention. 
Antibody titers of 1:400 and below indicate the necessity of revaccination.    
Taking into account the experimental data, we analyzed the individual immune response of 
ten patients vaccinated with Encepur® Adults three and five years later after a course of 
three vaccine injections. We determined that this vaccine enables long-term production of 
antibodies which remains for up to seven years (observation time). As a rule, repeated 
vaccination contributes to formation of high-avidity antibodies [Leonova GN & Pavlenko EV, 
2009] which usually have high affinity to specific antigen sites and are able to eliminate 
antigen actively. A considerable part of immune sera of vaccinated patients contained avid 
antibodies with high AI three years later after a full course of vaccination, and moderate AI 
five years later after vaccination. It reached the mean value in half of cases, and a lower 
value in the rest ones. In other words, patients with antigen titer of 1:400 and below, as well 
as those with low avidity should be revaccinated in five years after full course of 
vaccination. This approach to vaccination time was confirmed by the work of Heinz FX et al. 
[2008], who recommended revaccinations for all patients vaccinated against TBEV, and five 
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years later, revaccination was not recommended only to the aged patients. Therefore, the 
data obtained on the threshold level of antibody titer (1:400) and determination of a minimal 
level of their immunological memory (1:100) helps to determine an immunological 
protectiveness of the vaccinated patients and duration of postvaccinal protective immunity 
and, thus, specify revaccination schedule. To obtain the maximal immunological and 
epidemiological effectiveness of vaccinal prevention against TBEV, individual approach to 
each patient is appropriate. Moreover, it may have medical and economic importance. 
5. Conclusion 
The most important characteristics of a vaccine preparation are its immunogenic activity 
and capability of a long-term preservation of antibodies in vaccinated patients. These 
characteristics should be taken into account when determining time of revaccinations. 
Immunization course with different vaccines made from western and Far Eastern TBEV 
subtypes, as well as combined vaccination with different preparations provided the high 
and stable seroconversion according to IFA and NT.  In accordance with the above 
experimental data, we have analysed an individual immune response in the patients 
vaccinated with Encepur® Adults three, five, and seven years later after the three-fold 
course of vaccination. It has been shown that this vaccine enables production of antibodies 
which are being preserved for a long time, up to seven years. As a rule, repeated vaccination 
contributed to formation of high-avidity antibodies [Leonova G.N., 2009] which usually had a 
high affinity level to specific antigen sites and were capable of active antigen elimination. 
Considerable part of immune sera from vaccinated patients contained avid antibodies which 
AI was still high three years later. Five and seven years later after full course of vaccination, 
AI decreased. High values of immune response after RV1 seven years later after full course 
of vaccination gave us strong evidence that the obtained data on antibody avidity, 
protective antibody titer threshold (1:400) and minimal level of immunological memory 
(1:100) are considered to be the crucial parameters in detection of immunoprotection of 
vaccinated patients. Based on these data, we suggest that revaccination schedule should be 
individual for a vaccinated patient for obtaining the maximal immunological and 
epidemiological effect of vaccinal TBE prevention. Such approach to determination of 
revaccination time is of economic and medical importance.  
6. Acknowledgements 
Authors are grateful to Novartis GmbH. The work was supported by the ISTC grant No. 
4006. 
7. References 
Bock HL, Klockmann U, Jungst C, Schindel-Kunzel F, Theobald K, Zerban R. (1990) A new 
vaccine against tick-borne encephalitis: initial trial in man including a dose–
response study. Vaccine 8(1), pp. 22–4. 
Briko NI. (2000). Criteria of vaccination effectiveness assessment, Vaktsinatsiya. 5, (11)  
http://medi.ru/doc/15b.1101.htm. 
Charrel RN, Attoui H, Butenko AM, et al. (2004).Tick-borne virus diseases of human interest 
in Europe. Clin Microbiol Infect. 10, (12), pp. 1040-55. 
www.intechopen.com
Evaluation of Immunological Efficiency  
Among Patients Vaccinated Against Tick-Borne Encephalitis 
 
211 
Chunikhin SP. & Leonova GN. (1985). Ecology and Geographic Distribution of Arboviruses. 
Meditsina Publishers, Moscow, 126 p.  
Dorokhova V.S. & Tatarinova L.G.  (1969).Tick-Borne Encephalitis Morbidity in Primorye 
Territory. Feral herd infections of Ural, Siberia and the Far East. Sverdlovsk, pp. 56-57. 
Ecker M, Allison SL, Meixner T, et al. (1999). Sequence analysis and genetic classification of 
tick-borne encephalitis viruses from Europe and Asia. J Gen Virol. 80, pp. 179–85. 
Heinz FX, & Kunz C. (2004).Tick-borne encephalitis and the impact of vaccination. Arch 
Virol. 18, pp. 201-205. 
Heinz FX, Holzmann H, Essl A, Kundt M. (2008). Analysis of the efficiency of tick-borne 
encephalitis vaccination in the population in the natural foci of Austria. Vopr 
Virusol. 53, (2).1, pp. 9-27. 
Holzmann H, Vorobyova MS, Ladyzhenskaya I et al. (1992). Molecular epidemiology of 
tick-borne-encephalitis virus: cross-protection between European and Far Eastern 
subtypes. Vaccine 10, pp. 345–49. 
Klockmann U., Krivanec K., Stephenson J.R., Hilfenhaus J. (1991). Protection against 
European isolates of tick-borne encephalitis virus after vaccination with a new tick-
borne encephalitis. Vaccine 9, pp. 210-212. 
Kunz CH., Heinz F, Hofmann H. (1980). Immunogenicity and Reactogenicity of a Highly 
Purified Vaccine against Tick-borne Encephalitis. J. Med. Virol. 6, pp.103-109. 
Kunz C. (2003). TBE vaccination and Austrian experience. Vaccine  21, pp. S1/50–S1/55. 
Leonova GN. (1997). Tick-borne encephalitis in Primorsky krai. ISBN 5-7442-0721-X, 
Vladivostok, 187 р.  
Leonova GN, Belikov SI, Kulakova NV, Pavlenko EV, Borisevich VG. (2004) Molecular 
typing of tick-borne encephalitis    
strains  isolated from human cases differing in the degree of severity in the south of 
Russian Far East. Mol Gen Mikrobiol Virusol (2), pp.:32–37  
Leonova GN, Pavlenko EV, Krylova NV. (2006). Vaccine Prevention of Tick-Borne Encephalitis. 
ISBM 5-9002274-32-2,  Vladivostok, 100 p.  
Leonova GN, Ternovoi VA, Pavlenko EV et al. (2007). Evaluation of vaccine Encepur® 
Adult for induction of human neutralizing antibodies against recent Far Eastern 
subtype strains of tick-borne encephalitis. Vaccine  25, pp. 895–901. 
Leonova GN, & Pavlenko EV. (2009). Characterization of neutralizing antibodies to Far 
Eastern of tick-borne encephalitis virus subtype and the antibody avidity for four 
tick-borne encephalitis vaccines in human. Vaccine 27, (21). pp. 2899-2904. 
Leonova G.N. (2009).The tick-borne Encephalitis: actual aspects. ISBM 978-5-91563-031-3, 
Moscow, 168 p. 
Loktev VB, Ternovoi VA, Netesov SV. (2007). Molecular genetic characterization of tick-
borne encephalitis virus. Vopr  Virusol 5, pp. 10–16                              
Memoirs on Elizabeth Nikolaevna Levkovich (under V.V.Pogodinoj's edition) Moscow, 
2001. 
Onishchenko G.G., Fedorov Y.M., Pakskina N.D. (2007). Organization of supervision for 
tick-borne encephalitis and it’s preventive maintenance in Russian Federation. Vopr 
Virusol. 5, pp. 8-10. 
Pavlenko E.V., Leonova G.N., Radchenko L.P. (2010). Cliniko-epidemiological analyses of 
tick-borne encephalitis in Primorye Territory. Des.delo  №1,  pp. 27-30. 
www.intechopen.com
  
Flavivirus Encephalitis 
 
212 
Petri E., Gniel D, Zent O. (2010). Tick-borne encephalitis (TBE) trends in epidemiology and 
current and future management. Travel Medicine and Infectious Disease 8, 233-245. 
Pogodina VV, Karan’ LS, Kolyasnikova NM, et al. (2007). The evolution of tick-borne  
encephalitis and the problem of  the pathogen evolution. Vopr Virusol. 5, 16–26. 
Prevention of tick-borne encephlitis. Sanitary and epidemiologic rules and regulations. SP 
3.1.3.2352-07,  2008. 
Smorodintsev A.A. & Doubov A.V. (1986). Tick- borne encephalitis and its prevention. 
Medicana, Moscow,  232 p. 
Takashima I, Hayasaka D, Goto A, et al. (2001). Epidemiology of tick-borne encephalitis 
(TBE) and phylogenetic analysis of TBE viruses in Japan and Far Eastern Russia. J 
Infect Dis. 54, pp. 1–11. 
Ternovoi VA, Protopopova EV, Chausov EV, et al. (2007). Novel variant of tick-borne 
encephalitis virus. Emerg Infect Dis 13 (10),  pp. 1574–78. 
Vereta LA, & Vorobyeva MS. (1990). Natural heterogeneity and aim-directed selection of strains of 
the tick-borne encephalitis virus. Moscow, 122 р. 
Vorobyova MS, Rasshchepkina MN, Ladyzhenskaya IP. (2007). Vaccine, immunoglobulin, 
and test kits for prevention and diagnostics of tick-borne encephalitis. Vopr Virusol. 
6, pp. 30-36. 
Zent O, Beran J, Jilg W, Mach T, Banzhoff A. (2003). Clinical evaluation of a polygeline-free 
tick-borne encephalitis vaccine for adolescents and adults. Vaccine. 21(7-8), pp.738-
41. 
Zent O, & Bro¨ker M. (2005). Tick-borne encephalitis vaccines: past and present. Expert Rev 
Vaccines. 4(5), pp. 747-55. 
Zent O, Hennig R, Banzhoff A, Bro¨ker M. (2005). Protection against tick-borne encephalitis 
with a new vaccine formulation free of protein-derived stabilizers. J Travel Med. 
12(2), pp. 85-93. 
www.intechopen.com
Flavivirus Encephalitis
Edited by Dr. Daniel Ruzek
ISBN 978-953-307-669-0
Hard cover, 478 pages
Publisher InTech
Published online 30, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Encephalitis is an inflammation of the brain tissue associated with clinical evidence of brain dysfunction. The
disease is of high public health importance worldwide due to its high morbidity and mortality. Flaviviruses, such
as tick-borne encephalitis virus, Japanese encephalitis virus, Murray Valley encephalitis virus, or St. Louis
encephalitis virus, represent important causative agents of encephalitis in humans in various parts of the
world. The book Flavivirus Encephalitis provides the most recent information about selected aspects
associated with encephalitic flaviviruses. The book contains chapters that cover a wide spectrum of subjects
including flavivirus biology, virus-host interactions, role of vectors in disease epidemiology, neurological
dengue, and West Nile encephalitis. Special attention is paid to tick-borne encephalitis and Japanese
encephalitis viruses. The book uniquely combines up-to-date reviews with cutting-edge original research data,
and provides a condensed source of information for clinicians, virologists, pathologists, immunologists, as well
as for students of medicine or life sciences.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Leonova G.N. (2011). Evaluation of Immunological Efficiency Among Patients Vaccinated Against Tick-Borne
Encephalitis, Flavivirus Encephalitis, Dr. Daniel Ruzek (Ed.), ISBN: 978-953-307-669-0, InTech, Available from:
http://www.intechopen.com/books/flavivirus-encephalitis/evaluation-of-immunological-efficiency-among-
patients-vaccinated-against-tick-borne-encephalitis
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
